Skip to main content
Addgene

pRVdG-N-P-M-nucBFP-EGFP-L
(Plasmid #52485)

Ordering

This material is available to academics and nonprofits only. Orders shipped outside the U.S. may require additional regulatory approval, as well as a non-refundable export license fee of $85. Please log in to view availability.
Item Catalog # Description Quantity Price (USD)
Plasmid 52485 Standard format: Plasmid sent in bacteria as agar stab 1 $85

Backbone

  • Vector backbone
    cSPBN (pSAD)
  • Backbone manufacturer
    Karl-Klaus Conzelmann & Matthias Schnell
  • Backbone size w/o insert (bp) 13851
  • Total vector size (bp) 15384
  • Vector type
    Mammalian Expression ; Rabies Virus

Growth in Bacteria

  • Bacterial Resistance(s)
    Ampicillin, 100 μg/mL
  • Growth Temperature
    37°C
  • Growth Strain(s)
    DH5alpha
  • Growth instructions
    DH5alpha at 37C
  • Copy number
    High Copy

Gene/Insert 1

  • Gene/Insert name
    nuclear mTagBFP
  • Alt name
    nucBFP
  • Species
    Synthetic
  • Insert Size (bp)
    813
  • Promoter CMV

Cloning Information for Gene/Insert 1

Gene/Insert 2

  • Gene/Insert name
    EGFP
  • Alt name
    Enhanced Green Fluorescent Protein
  • Species
    Synthetic
  • Insert Size (bp)
    720
  • Promoter CMV

Cloning Information for Gene/Insert 2

Terms and Licenses

Trademarks:
  • Zeocin® is an InvivoGen trademark.

Depositor Comments

Alternative plasmid name: pRVdG-4nB5E

How to cite this plasmid ( Back to top)

These plasmids were created by your colleagues. Please acknowledge the Principal Investigator, cite the article in which the plasmids were described, and include Addgene in the Materials and Methods of your future publications.

  • For your Materials & Methods section:

    pRVdG-N-P-M-nucBFP-EGFP-L was a gift from Sebastian Seung (Addgene plasmid # 52485 ; http://n2t.net/addgene:52485 ; RRID:Addgene_52485)
  • For your References section:

    Axonal and subcellular labelling using modified rabies viral vectors. Wickersham IR, Sullivan HA, Seung HS. Nat Commun. 2013;4:2332. doi: 10.1038/ncomms3332. 10.1038/ncomms3332 PubMed 23945836